• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CBD Life Sciences Inc. (CBDL) Targets Amazon Marketplace for Strategic Business Enhancements

    10/1/24 8:00:00 AM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary
    Get the next $YCBD alert in real time by email

    With Amazon's market value increasing by more than $400 billion in 2024, CBD Life Sciences Inc. is poised for new revenue growth with top-selling CBD Pain Relief Roll-On and Pet Treats.

    SCOTTSDALE, AZ / ACCESSWIRE / October 1, 2024 / CBD Life Sciences Inc. (OTC:CBDL), a fast-growing leader in the CBD industry, is excited to announce its application to list on Amazon Marketplace. Following its successful launch on Walmart Marketplace, this strategic expansion promises to significantly increase the company's e-commerce footprint, offering its top-selling CBD Pain Relief Cream Roll-On and CBD Pet Treats to millions of Amazon customers globally.

    The move underscores CBD Life Sciences' commitment to rapidly scaling its distribution network, with Amazon representing a major growth opportunity in the company's multi-channel retail strategy.

    Unlocking New Revenue Potential through Amazon
    With Amazon's vast customer base of over 300 million active users, CBDL stands to capture substantial market share in the booming CBD industry. Building on a 1405.46% revenue increase since February 2024, the addition of Amazon to CBDL's retail arsenal is expected to create new revenue streams, positioning the company for exponential growth in the near future.

    "Entering the Amazon Marketplace is a key part of our aggressive expansion strategy," said Lisa Nelson, President and CEO of CBD Life Sciences Inc. "We have already seen tremendous success with our product launches on Walmart Marketplace. By leveraging Amazon's unparalleled reach, we expect to see accelerated revenue growth and increased brand awareness across multiple demographics."

    Nelson emphasized that the Amazon platform offers unique advantages for scaling high-demand products like the CBD Pain Relief Cream Roll-On-a favorite among consumers seeking targeted, fast-acting pain relief-and CBD Pet Treats, which address common issues such as anxiety and joint pain in pets. "This is a pivotal moment for CBDL, as we position ourselves to dominate new segments of the market with proven products that resonate with both human and pet health-conscious customers."

    A Growth Opportunity for Investors
    For investors, this expansion highlights a pivotal opportunity to invest in a rapidly growing CBD company with a proven track record of success. CBDL's aggressive entrance into major retail platforms positions it at the forefront of an industry projected to surpass $20 billion by 2025.

    "The CBD market is primed for explosive growth, and CBDL is well-positioned to capitalize on this momentum," said Nelson. "Our commitment to innovation and quality has earned us significant revenue increases over the past year, and with Amazon, we're setting the stage for even more significant growth."

    CBD Life Sciences Inc. continues to pursue other lucrative partnerships with e-commerce giants and retail chains, further enhancing its potential to deliver robust returns for current and future investors. The Amazon launch is expected to drive substantial increases in sales and offer unparalleled brand visibility, with millions of potential customers just a click away.

    Join the Growth - Invest in CBD Life Sciences Inc.
    With its expanding product portfolio, increasing distribution channels, and strong leadership team, CBD Life Sciences Inc. offers an exceptional opportunity for investors looking to enter the booming CBD space. By integrating with Amazon, CBDL is set to amplify both revenue and market share, making this an opportune time for investors to engage with a company poised for sustained long-term growth.

    About CBD Life Sciences Inc.

    CBD Life Sciences Inc. (OTC:CBDL) is a recognized leader in the CBD industry, offering a range of premium-quality CBD products designed to improve health and well-being for humans and pets. The company's diverse product portfolio includes topicals, tinctures, edibles, and pet care products. With a relentless focus on innovation and customer satisfaction, CBDL is positioned for rapid growth in one of the fastest-growing sectors of the health and wellness industry.

    Follow our social media for the latest updates!

    X: https://www.x.com/CBDL_StockOTC
    Instagram: https://www.instagram.com/cbd.vault
    IR Contact: [email protected]

    Forward-Looking Statements
    Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

    Safe Harbor Statement
    This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.

    Contact Information

    Lisa Nelson
    CEO
    [email protected]
    4802091720

    SOURCE: CBD Life Sciences Inc.



    View the original press release on accesswire.com

    Get the next $YCBD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $YCBD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $YCBD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    cbdMD Launches Clinical Healthcare Channel to Support First Federal Pathway for Hemp-Derived CBD in Medicare

    Company brings one of the only combined clinical and toxicological safety dataset in the hemp-derived CBD category into a new provider channel as CMS activates cannabinoid access within value-based care modelsCHARLOTTE, N.C., April 1, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), a leader in science-driven cannabinoid products, today announced the launch of its clinical healthcare channel, positioning the Company to support physicians, health systems, and value-based care organizations as federal policy establishes structured pathways for hemp-derived cannabinoid products within Medicare programs.

    4/1/26 8:30:00 AM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    cbdMD Reports Sequential Revenue Growth, Improved Liquidity, and Strong Start to Fiscal 2026

    CHARLOTTE, N.C., Feb. 17, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD, Bluebird Botanicals, Paw CBD, along with its THC beverage brand Oasis today announced its financial results for the first quarter of fiscal year ended December 31, 2025. cbdMD reported 12% sequential revenue growth and improved liquidity in the first quarter of fiscal 2026, reflecting continued stabilization of the core business and early benefits from recent strategic actions."We a

    2/17/26 4:10:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    cbdMD, Inc. to Host Conference Call to Discuss December 31, 2025 First Quarter Results

    CHARLOTTE, N.C., Feb. 12, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:20 p.m., Eastern Time, on Tuesday, February 17, 2026, to discuss the company's December 31, 2025 first quarter financial results and business progress. CONFERENCE CALL DETAILS Tuesday, February 17, 2026, 4:20 p.m. Eastern Time USA/Canada: 888-880-3330 Webcast/Webcast Replay link - available through February 17, 2027: https://app.webinar.net/YzX7D4ynvN2 About cbdMD, Inc.

    2/12/26 5:31:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $YCBD
    SEC Filings

    View All

    cbdMD Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - cbdMD, Inc. (0001644903) (Filer)

    4/1/26 4:05:49 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form EFFECT filed by cbdMD Inc.

    EFFECT - cbdMD, Inc. (0001644903) (Filer)

    3/5/26 12:15:15 AM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 424B4 filed by cbdMD Inc.

    424B4 - cbdMD, Inc. (0001644903) (Filer)

    3/4/26 5:24:35 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $YCBD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Crosnoe Clark R. sold $1,276,842 worth of shares (550,701 units at $2.32) (SEC Form 4)

    4 - cbdMD, Inc. (0001644903) (Issuer)

    12/19/25 9:16:26 AM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    CEO and CFO Kennedy Thomas Ronan was granted 445,000 shares, increasing direct ownership by 648% to 513,722 units (SEC Form 4)

    4 - cbdMD, Inc. (0001644903) (Issuer)

    12/2/25 6:29:31 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    Director Porter Jeffrey H was granted 1,572 shares (SEC Form 4)

    4 - cbdMD, Inc. (0001644903) (Issuer)

    5/20/25 5:23:40 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $YCBD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald resumed coverage on cbdMD with a new price target

    Cantor Fitzgerald resumed coverage of cbdMD with a rating of Neutral and set a new price target of $3.25 from $4.10 previously

    6/18/21 6:26:36 AM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    Cantor Fitzgerald reiterated coverage on cbdMD with a new price target

    Cantor Fitzgerald reiterated coverage of cbdMD with a rating of Neutral and set a new price target of $4.30 from $3.60 previously

    1/29/21 4:54:10 AM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $YCBD
    Leadership Updates

    Live Leadership Updates

    View All

    cbdMD, Inc. Announces Shareholder Approval of Automatic Conversion of Series A Preferred Stock and Other Results from Annual Meeting

    Charlotte, North Carolina--(Newsfile Corp. - April 10, 2025) - cbdMD, Inc. (NYSE:YCBD) (NYSE:YCBDPA) (the "Company" or "cbdMD") one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with its functional mushroom brand ATRx Labs and emerging THC-infused seltzer brand Herbal Oasis announced today that at the Company's annual meeting of shareholders held on April 10, 2025, that its Common Stock holders and 8% Series A Cumulative Convertible Preferred Stock (the "Preferred Stock") holders approved the automatic conversion (the "Conversion") of shares of the Company's Preferred Stock into shares of the Comp

    4/10/25 5:57:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    cbdMD Announces Partnership with Medical Advisor, Dr. Lucille Vega

    Charlotte, North Carolina--(Newsfile Corp. - June 22, 2023) - cbdMD (NYSE:YCBD), one of the nation's leading providers of premium cannabidiol (CBD) products, is delighted to announce the appointment of Dr. Lucille Vega as their new medical advisor. This collaboration marks an exciting chapter for both parties, as they play a pivotal role in educating the public about the numerous benefits of CBD and cbdMD's commitment to quality and transparency.As a brand that's renowned for its commitment to quality and innovation, cbdMD's comprehensive line of products spans across various categories and caters to a diverse range of consumer needs. By partnering with Dr. Vega, a highly qualified and passi

    6/22/23 9:00:00 AM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    cbdMD Welcomes Shannon Charles as Chief Marketing Officer

    Charlotte, North Carolina--(Newsfile Corp. - January 11, 2023) - cbdMD, Inc. (NYSE:YCBD) (NYSE:YCBDPA), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces the appointment of Shannon Charles as Chief Marketing Officer. Shannon is a veteran in health and wellness with over a decade of success in the Natural Product Industry. She has a proven record in driving growth across B&M retail, warehouse club stores, ecommerce, as well as international markets. Shannon's leadership has supported the successful brand stories of Naturade, NeoCell, and NutraNext, which the latter was ultimately acquired by The Clorox Co during her tenure. "We are thrilled to h

    1/11/23 12:33:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $YCBD
    Financials

    Live finance-specific insights

    View All

    cbdMD Reports Sequential Revenue Growth, Improved Liquidity, and Strong Start to Fiscal 2026

    CHARLOTTE, N.C., Feb. 17, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD, Bluebird Botanicals, Paw CBD, along with its THC beverage brand Oasis today announced its financial results for the first quarter of fiscal year ended December 31, 2025. cbdMD reported 12% sequential revenue growth and improved liquidity in the first quarter of fiscal 2026, reflecting continued stabilization of the core business and early benefits from recent strategic actions."We a

    2/17/26 4:10:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    cbdMD, Inc. to Host Conference Call to Discuss December 31, 2025 First Quarter Results

    CHARLOTTE, N.C., Feb. 12, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:20 p.m., Eastern Time, on Tuesday, February 17, 2026, to discuss the company's December 31, 2025 first quarter financial results and business progress. CONFERENCE CALL DETAILS Tuesday, February 17, 2026, 4:20 p.m. Eastern Time USA/Canada: 888-880-3330 Webcast/Webcast Replay link - available through February 17, 2027: https://app.webinar.net/YzX7D4ynvN2 About cbdMD, Inc.

    2/12/26 5:31:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    cbdMD Reports Third Consecutive Year of Operating Improvement, Strengthens Balance Sheet, and Regains NYSE American Continued Listing Compliance

    CHARLOTTE, N.C., Dec. 19, 2025 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with hemp derived THC beverage line Herbal Oasis today announced our financial results for the full fiscal year ended September 30, 2025. For fiscal year 2025, cbdMD delivered its third consecutive year of operational and financial improvement, reflecting disciplined cost management, focused execution, and continued investment in quality and science. The Company

    12/19/25 4:10:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $YCBD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by cbdMD Inc. (Amendment)

    SC 13D/A - cbdMD, Inc. (0001644903) (Subject)

    8/12/22 4:02:14 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form SC 13D/A filed by cbdMD Inc. (Amendment)

    SC 13D/A - cbdMD, Inc. (0001644903) (Subject)

    6/21/22 7:52:33 AM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form SC 13D/A filed by cbdMD Inc. (Amendment)

    SC 13D/A - cbdMD, Inc. (0001644903) (Subject)

    5/19/22 4:05:28 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary